Differential Gene Expression May Predict Response to Somatostatin Analogues (SSAs) in Gastrointestinal (GI) Neuroendocrine Tumors (NETs)

#2868

Introduction: SSAs are commonly used to treat GI NETs as they have anti-secretory and antiproliferative effects. However, genetic markers predicting response to SSAs are lacking.

Aim(s): We performed a genome wide evaluation of gene expression changes associated with response to SSAs in GI NETs.

Materials and methods: RNA was extracted from FFPE conserved tissue of 27 patients with NETs who previously received SSA treatment. Samples were hybridized against the human Clariom S Assays (Affymetrix). Data analysis was performed using the Bioconductor / R-package pd.clariom.s.human. Genes with at least 1.5-fold regulation and a p-value <0.01 were considered significant. Pathway and functional analysis were performed using WebGestalt (2013 edition).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Teufel A

Authors: Teufel A, Evert K, Itzel T, Evert M, Koch C,

Keywords: NET gene expression profiling, SSA somatostatin analoga,